SCHEMBL11945933

SCHEMBL11945933

CC(C)OCCCNC(=O)c1cccc(CNS(=O)(=O)N2CCN(c3cnn(-c4cccc(Cl)c4)c(=O)c3OCC3(C)CC3)CC2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.37
▸ POLB P06746 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ NCOA2 Q15596 1/20 0.36
▸ NCOA1 Q15788 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ NCOA3 Q9Y6Q9 1/20 0.36
▸ MAPT P10636 7/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ TP53 P04637 5/20 0.34
▸ PAX8 Q06710 1/20 0.34
▸ DRD2 P14416 3/20 0.34
▸ HTR1A P08908 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945931 0.88 POLB (0.40) LMNAPOLBCYP3A4CYP2C19PPARG
SCHEMBL11945932 0.88 POLB (0.41) LMNAPOLBCYP3A4CYP2C19PPARG
SCHEMBL11945919 0.88 POLB (0.39) LMNAPOLBCYP3A4CYP2C19PPARG
SCHEMBL11945939 0.87 POLB (0.39) LMNAPOLBCYP3A4CYP2C19PPARG
SCHEMBL11945928 0.87 POLB (0.42) LMNAPOLBCYP3A4CYP2C19PPARG
SCHEMBL11945907 0.86 POLB (0.41) LMNAPOLBCYP3A4CYP2C19PPARG
SCHEMBL11945936 0.85 ALDH1A1 (0.40) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11945917 0.85 NPBWR1 (0.44) LMNAPOLBCYP3A4CYP2C19PPARG
SCHEMBL11945940 0.84 POLB (0.40) LMNAPOLBCYP3A4CYP2C19PPARG
SCHEMBL11945920 0.83 POLB (0.42) LMNAPOLBCYP3A4CYP2C19PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA LMNA 929/4885POLB 1088/4885CYP3A4 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback